Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes Body Care Children Complications Defeat Diabetes Foundation Drugs    » ACE Inhibitor    » Actos    » Alternative Medicine    » Aspirin    » Avandia    » Byetta    » Drugs    » Exenatide    » Glargine    » Glucophage    » Insulin    » Januvia    » Lantus    » Liraglutide    » Metformin    » Recall    » Research    » Rosiglitazone    » Self-Management    » Statins    » Sulfonylureas    » Victoza Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research Risks Self-Management Supplements Type 1 Warning Signs

 

 

 

     

Drugs » Rosiglitazone

Search our News Articles Archives for diabetes and health news. Search by word or phrase.  The latest article will appear first.

Search For:  

Search in all categories / subcategories
Search in current category / subcategory

Treating Type 2 Diabetes in Youth Posted: Monday, May 07, 2012

Rising childhood obesity in America has brought more cases of type 2 diabetes in youth. A combination of 2 diabetes drugs was more effective in treating youth with type 2 diabetes than metformin alone, according to a new study.

FDA Spells Out Who Can Use Rosiglitazone Posted: Sunday, February 13, 2011

Rosiglitazone label updated to include elevated risk of cardiovascular events.

A Systematic Review of Newer Drugs for Glucose Control Posted: Sunday, February 06, 2011

The National Institute for Health and Clinical Excellence (NICE) issued an updated Guideline for newer drugs for the management of all aspects of Type 2 diabetes. The guidelines review the newer agents from four classes with a cost analysis.

More Evidence Actos and Avandia Increases Risk of Bone Fracture Posted: Monday, August 09, 2010

The popular diabetes drugs Actos and Avandia boost the risk of fracture in older women, according to findings from a new study that echo those of earlier research.

Diabetes and Cardiology Groups Stay Firm on Rosiglitazone Posted: Sunday, July 04, 2010

In response to new Medicare data showing greater elevations in stroke, heart failure, and death risk with rosiglitazone compared with pioglitazone (Actos), the AHA issued a statement to the media reiterating its stance that there are insufficient data to support the choice of one over the other. And both the AHA and the ADA emphasized the need for patients to be informed of the new evidence, but not to panic.

TZD Patients Are 50% More Likely to Develop Bone Fractures Posted: Sunday, March 07, 2010

A Henry Ford Hospital study finds women with Type 2 diabetes who take a commonly prescribed class of medications called TZD's to treat insulin resistance may be at a higher risk for developing bone fractures within 1 year of taking the medication.

FDA Reviewers Urge Pulling Rosiglitazone Posted: Sunday, February 28, 2010

Two FDA reviewers have recommended that the diabetes drug rosiglitazone (Avandia) be pulled from the market because of its link to major cardiac events.

Rosiglitazone Plus Metformin Prevents Bone Loss Posted: Wednesday, June 24, 2009

Recent research shows that rosiglitazone decreases bone mineral density in healthy humans and appears to increase fractures in women with Type 2 diabetes, compared with those receiving metformin or another diabetes medication.

Overall Cardiovascular Safety of Rosiglitazone Confirmed in 5˝ Year Study Posted: Wednesday, June 10, 2009

Scores comparable to standard therapy on heart attacks, strokes and CV death but doubled incidence of heart failure warrants monitoring by physician.

Stopping Avandia Increases Blood Sugar Levels Posted: Wednesday, April 29, 2009

Study found diabetics who discontinued use of the drug showed a worsening of control and management of their diabetes.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.